Answers are grounded in this paper and cite their sources.
Antibody-drug conjugates demonstrate efficacy in advanced breast cancer, indicating a need for improved clinical strategies.
Antibody-drug conjugates are redefining treatment options in advanced breast cancer, demonstrating efficacy across all breast cancer subtypes. However, their rapid clinical expansion has resulted in several unresolved challenges, including the need for rational sequencing strategies, appropriate and ethical trial design, drug tolerability, and the limitation of mono-national development programs.
No takes yet. Share an insight, caveat, or question.
Notini et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: